Bayesian Estimation in Bioequivalence Study

Title & Authors
Bayesian Estimation in Bioequivalence Study
Lee, Seung-Chun;

Abstract
The classical two-period, two-sequence crossover design is no longer sufficient to assess various demands in a bioequivalence study. For instance, to estimate the within-subject and between-subject variances of test and reference formulations separately, it is necessary to use a replicate design in which each subject receives at least the reference formulation in two periods. Several designs were studied to satisfy the demands. It is provided a unified Bayesian approach applicable to those study designs. The benefit of the method in the bioequivalence study is discussed.
Keywords
Gibbs sampling;crossover design;bioequivalence;linear mixed model;
Language
English
Cited by
References
1.
Anderson, S. and Hauck, W. W. (1990). Consideration of individual bioequivalence, Journal of Pharmacokinetics and Biopharmaceutic, 18, 259-273.

2.
Best, N. G., Tan, K. K. C., Gilks, W. R. and Spiegelhalter, D. J. (1995). Estimation of population pharmacokinetics using the Gibbs sampler, Journal of Pharmacokinetics and Biopharmaceutics, 23, 407-435.

3.
Carrasco, L. and Jover, L. (2003). Assessing individual bioequivalence using structural equation model, Statistics in Medicine, 15, 1619-1634.

4.
Chow, S. C., Shao, J. and Wang, H. (2003). Statistical test for population bioequivalence, Statistica Sinica, 13, 539-554.

5.
Daniels, M. D. and Kass, R. E. (1999). Nonconjugate Bayesian estimation of covariance matrices and its use in hierarchical models, Journal of the American Statistical Association, 94, 1254-1263.

6.
Europian Medical Agency (2010). Guideline on the Investigation of Bioequivalence, Committee for Medicinal Products for Human Use, CPMP/EWP/QWP/1401/98 Rev. 1., London.

7.
Food and Drug Administration (1997). In Vivo Bioequivalence Studies Based on Population and Individual Bioequivalence Approached: Guidance for Industry, Center for Drug Evaluation and Research, Rockville, MD 20857.

8.
Food and Drug Administration (2003). Bioavailability and Bioequivalence Studies for Orally Administered Drug Products: General Considerations, Center for Drug Evaluation and Research, Rockville, MD.

9.
Gelman, A. (2006). Prior distributions for variance parameters in hierarchical models, Bayesian Analysis, 1, 515-533.

10.
Hauck, W. W. and Anderson, S. (1992). Types of bioequivalence and related statistical considerations, International Journal of Clinical Pharmacology, Therarp, and Toxicology, 30, 181-187.

11.
Hauschke, D., Steinijas, V. and Pigeot, I. (2007). Bioequivalence Studies in Drug Development: Methods and Applications, John Wiley & Sons, New York.

12.
Hobert, J. P. and Casella, G. (1996). The effect of improper priors on Gibbs sampling in hierarchical linear mixed models, Journal of the American Statistical Association, 91, 1461-1473.

13.
Hsuan, F. C. and Reeve, R. (2003). Assessing individual bioequivalence with high-order cross-over designs: a unified procedure, Statistic in Medicine, 22, 2847-2860.

14.
Hylsop, T., Hsuan, F. and Holder, D. J. (2000). A small sample confidence interval approach to access individual bioequivalence, Statistic in Medicine, 19, 2885-2897.

15.
Jung, G.-J., Lim, N.-K. and Park, S.-G. (2010). Individual bioequivalence tests under 3 ${\times}$ 2 design, The Korean Journal of Applied Statistics, 23, 139-150.

16.
Kass, R. E. and Natarajan, R. (2006). A default conjugate prior for variance components in generalized linear mixed models (Comment on article by Browne and Draper), Bayesian Analysis, 1, 535-542.

17.
Lee, S.-C. and Lee, D. (2002). Bayesian analysis of multivariate threshold animal models using Gibbs sampling. Journal of the Korean Statistical Society 31, 177-198.

18.
Lunn, D. J., Best, N., Thomas, A. and Wakefield, J. (2002). Bayesian analysis of population PK/PD models: General concepts and software, Journal of Pharmacokinetics and Pharmacodynamics, 29, 271-307.

19.
Natarajan, R. and Kass, R. E. (2000). Reference Bayesian methods for general linear mixed models, Journal of American Statistical Association, 95, 227-237.

20.
Oh, H. S., Ko, S.-G. and Oh, M.-S. (2003). A Bayesian approach to accessing population bioequivalence in a 2 ${\times}$ 2 crossover design, Journal of Applied Statistics, 30, 881-891.

21.
Shao, J., Chow, S. C. and Wang, H. (2002). Individual bioequivalence testing under $2{times}3$ designs, Statistics in Medicine, 21, 629-648.

22.
Tiao, G. C. and Tan, W. Y. (1965). Bayesian analysis of random-effects models in the analysis of variance. I. Posterior distribution of variance components, Biometrika, 52, 37-53.

23.
Wang, C. S., Rutledge, J. J. and Gianola, D. (1994). Bayesian analysis of mixed linear models via Gibbs sampling with an application to litter size of Iberian pigs, Genetique, Selection, Evolution, 26, 91-115.

24.
Zeger, S. L. and Karim, M. R. (1991). Generalized linear models with random effects; A Gibbs sampling approach, Journal of the American Statistical Association, 86, 79-86.